Published in Anal Chem on July 01, 1968
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol (1976) 1.05
Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br J Pharmacol (1971) 0.99
Preparative microfluidic electrosynthesis of drug metabolites. ACS Med Chem Lett (2013) 0.91
Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. Br J Clin Pharmacol (1975) 0.85
Chlorpromazine levels in plasma and milk of nursing mothers. Br J Clin Pharmacol (1978) 0.76
Pharmacology of chlorpromazine: clinical studies. Br J Pharmacol (1971) 0.75
The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Br J Clin Pharmacol (1974) 0.75
Electrophysiological indicator of awakening from coma. Lancet (1993) 1.61
Clinical and biochemical comparison of clorazepate and diazepam. Psychol Med (1974) 1.46
Influence of posture on plasma nitroglycerin. Br J Clin Pharmacol (1985) 1.45
Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc R Soc Med (1971) 1.43
A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med (1992) 1.42
Factors affecting chlorpromazine plasma levels in psychiatric patients. Arch Gen Psychiatry (1970) 1.42
Uptake of disodium cromoglycate in obstructive airways disease. Clin Allergy (1973) 1.38
Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. Am J Med (1994) 1.38
Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther (1973) 1.36
Plasma protein binding of chlorpromazine. J Pharm Pharmacol (1970) 1.30
Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients. Life Sci (1968) 1.29
The physiological disposition of chlorpromazine in the rat and dog. Proc Soc Exp Biol Med (1970) 1.28
Studies of delayed-action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine. Clin Pharmacol Ther (1970) 1.28
Plasma concentrations in the monkey (Macaca mulatta) of six related benzodiazepines after intraperitoneal injection [proceedings]. Br J Pharmacol (1976) 1.24
Treatment of lactic acidosis with dichloroacetate. N Engl J Med (1983) 1.11
Plasma-trifluoperazine concentrations during high dose therapy. Lancet (1981) 1.01
Preparation and stability of indomethacin solutions. Can J Physiol Pharmacol (1982) 1.00
Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther (1985) 1.00
Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci (1972) 0.99
Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br J Pharmacol (1971) 0.99
Chlorpromazine plasma levels and effects. Arch Gen Psychiatry (1970) 0.93
Amikacin sulfate in mares: pharmacokinetics and body fluid and endometrial concentrations after repeated intramuscular administration. Am J Vet Res (1984) 0.92
Nitroglycerin levels after administration via transdermal therapeutic system or nitroglycerin ointment. Lancet (1984) 0.92
Disposition of glutethimide in man. Clin Pharmacol Ther (1971) 0.92
Effect of dose and ointment application technique on nitroglycerin plasma concentrations. Pharmacotherapy (1983) 0.91
Event-related potentials--neurophysiological tools for predicting emergence and early outcome from traumatic coma. Intensive Care Med (1996) 0.91
Interaction of glutethimide and phenobarbitone with ethanol in man. J Pharm Pharmacol (1972) 0.91
Methods for study of fluphenazine kinetics in man. J Pharm Pharmacol (1976) 0.91
Letter: A note on the analysis of disodium cromoglycate (Intal) in human urine. J Pharm Pharmacol (1973) 0.90
Destruction of chlorpromazine during absorption by rat intestine in vitro. Br J Pharmacol (1970) 0.89
Double-blind trial of fluphenazine decanoate. Lancet (1972) 0.88
Acute tolerance to a sedative in man. Br J Pharmacol (1970) 0.88
Pharmacokinetics of closely related benzodiazepines. Br J Clin Pharmacol (1979) 0.88
The physiological disposition of 2(2,6-dichloroanilino)-2-imidazoline (St-155). Biochem Pharmacol (1969) 0.88
Chronic toxicity of dichloroacetate: possible relation to thiamine deficiency in rats. Fundam Appl Toxicol (1990) 0.88
Theoretical changes in drug distribution resulting from changes in binding to plasma proteins and to tissues. J Pharm Pharmacol (1970) 0.87
Behavioural and pharmacokinetic studies in the monkey (Macaca mulatta) with diazepam, nordiazepam and related 1,4-benzodiazepines. Br J Pharmacol (1977) 0.87
Proceedings: Clinical pharmacology of chlorpromazine. Br J Pharmacol (1972) 0.87
Plasma-fluphenazine concentrations after injection of long-acting esters. Lancet (1978) 0.86
Relative bioavailability of trimeprazine tablets investigated in man using HPLC with electrochemical detection. J Pharm Pharmacol (1986) 0.85
Clinical effects and metabolism of diazepam in patients with chronic liver disease. Clin Sci (Lond) (1982) 0.84
Improved EMIT analysis for lidocaine. Clin Chem (1985) 0.84
Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol (1997) 0.84
Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry (1978) 0.83
Concentration-effect relationships with major and minor tranquilizers. Clin Pharmacol Ther (1974) 0.83
Long-acting phenothiazines in schizophrenia. Br Med J (1971) 0.83
The form and distribution of auditory evoked potentials and CNVs when stimuli and responses are lateralized. Prog Brain Res (1980) 0.83
Bratton-Marshall and liquid-chromatographic methods compared for determination of sulfamethazine acetylator status. Clin Chem (1981) 0.83
Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol (1979) 0.82
Quantitative electroencephalographic evaluation of non-fatal and fatal traumatic coma. Electroencephalogr Clin Neurophysiol (1998) 0.82
Analysis of plasma trifluoperazine by gas chromatography and selected ion monitoring. J Chromatogr (1982) 0.81
Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit (1987) 0.80
Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine. Dis Nerv Syst (1973) 0.80
Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug. J Pharm Pharmacol (1969) 0.80
Drug distribution and effect. J R Coll Physicians Lond (1970) 0.79
In vivo folate kinetics during chronic supplementation of human subjects with deuterium-labeled folic acid. J Nutr (1992) 0.79
Stability, human blood distribution and rat tissue localization of promazine and desmonomethylpromazine. Biopharm Drug Dispos (1990) 0.78
Late slow wave components of auditory evoked potentials: their cognitive significance and interaction. Electroencephalogr Clin Neurophysiol (1981) 0.78
Urinary excretion of chlorpromazine metabolites following single doses and in steady-state conditions. Res Commun Chem Pathol Pharmacol (1971) 0.78
Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol (1985) 0.77
Pharmacokinetics and pharmacodynamics of acepromazine in horses. Am J Vet Res (1994) 0.77
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology (Berl) (1985) 0.77
Localization of basic drugs in the submaxillary gland. Biochem Pharmacol (1969) 0.77
Contingent negative variation and slow waves in a short interstimulus interval go-nogo task situation. Ann N Y Acad Sci (1984) 0.77
Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets. Biopharm Drug Dispos (1992) 0.77
Preparation and stability of intravenous solutions of sodium dichloroacetate (DCA). J Parenter Sci Technol (1992) 0.77
Animal model for investigation of fluphenazine kinetics after administration of long-acting esters. Biopharm Drug Dispos (1981) 0.76
Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin. Clin Pharmacol Ther (1984) 0.76
Event-related potentials as indicants of structural and functional damage in closed head injury. Prog Brain Res (1980) 0.76
Unwanted effects of fluphenazine enanthate and decanoate. Lancet (1979) 0.76
The strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol (1985) 0.76
Analysis, disposition and pharmacokinetics of nitroglycerin. Biopharm Drug Dispos (1985) 0.75
Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. Br J Clin Pharmacol (1982) 0.75
Plasma level studies in psychotropic evaluation. Br J Clin Pharmacol (1976) 0.75
Proceedings: A microsomal oxidase system in rat intestinal mucosa. Br J Pharmacol (1975) 0.75
Relation between binding to plasma protein, apparent volume of distribution, and rate constants of disposition and elimination for chlorpromazine in three species. J Pharm Pharmacol (1972) 0.75
Changes in reaction time and drug plasma concentrations after nitrazepam and glutethimide. Br J Clin Pharmacol (1977) 0.75
Disposition of disodium cromoglycate administered in three particle sizes. Br J Clin Pharmacol (1975) 0.75
Commentary: therapeutic monitoring of antipsychotic drugs. J Clin Psychopharmacol (1997) 0.75
Applications of cognitive ERPs in neurosurgical and neurological patients. Electroencephalogr Clin Neurophysiol Suppl (1986) 0.75
Lack of interaction of ranitidine with amitriptyline. Eur J Clin Pharmacol (1987) 0.75
A welfare village. J Coll Gen Pract (1966) 0.75
Pharmacology of combined antidepressant/H2-blocking drug therapy. Psychopharmacol Bull (1986) 0.75
Gas-chromatographic separation of chlorpromazine, diazepam and N-desmethyldiazepam. J Pharm Pharmacol (1975) 0.75
Extent of drug absorption at the time of peak plasma concentration in an open one-compartment body model with first-order absorption. J Pharm Sci (1990) 0.75
A comparison of early event-related potentials in two target detection tasks. Ann N Y Acad Sci (1984) 0.75
Proceedings: Disposition of disodium cromoglycate administered in three particle sizes. J Pharm Pharmacol (1974) 0.75
Proceedings: Hydrophobic character of 15 model chlorpromazine metabolites determined from partition ratios in mixed solvents. Br J Pharmacol (1974) 0.75
Evaluation of equilibrium dialysis volume shifts: a comment. J Pharmacokinet Biopharm (1984) 0.75
Lactate-lowering effect of dichloroacetic acid: a model for investigation of anxiolytic drugs? Psychopharmacol Bull (1989) 0.75
Assay of 7-hydroxychlorpromazine, and failure to detect more than small quantities, in plasma of responding schizophrenics. Psychopharmacol Commun (1975) 0.75
Chromatographic separation of thioridazine sulphoxide and N-oxide diastereoisomers: identification as metabolites in the rat. J Pharm Pharmacol (1986) 0.75
Interaction of phenobarbitone and ethanol in mice studied from dose-response curves and drug concentrations in blood. J Pharm Pharmacol (1974) 0.75
Analysis of N-benzoyl-L-tyrosyl-p-aminobenzoic acid (bentiromide) metabolites in urine by ion-pair high-performance liquid chromatography. J Chromatogr (1985) 0.75
Transdermal nitroglycerin patches. Clin Pharm (1985) 0.75
Chemical stability of sublingual nitroglycerin tablets carried on paramedic vehicles. Am J Emerg Med (1988) 0.75
Calculation of fraction bound in equilibrium dialysis with special reference to drug losses by decomposition and adsorption. Biopharm Drug Dispos (1986) 0.75
Transdermal nitroglycerin. Lancet (1984) 0.75
Cumulative excretion of succinonitrile in mice. Biochem Pharmacol (1975) 0.75
Effect of Vacutainer tubes on lidocaine protein binding. Drug Intell Clin Pharm (1987) 0.75